Indoramin

Oral
Benign prostatic hyperplasia

Oral
Hypertension

Known heart failure. Concomitant use with MAOIs.

Patient with history of depression, epilepsy, Parkinson's disease. Patient undergoing cataract surgery. Renal and hepatic impairment. Elderly. Pregnancy and lactation.

Significant: CNS effects (e.g. drowsiness, sedation), extrapyramidal reactions.
Gastrointestinal disorders: Nausea, diarrhoea, xerostomia.
General disorders and administration site conditions: Fatigue.
Investigations: Weight gain.
Nervous system disorders: Headache.
Psychiatric disorders: Depression.
Reproductive system and breast disorders: Ejaculation failure.
Respiratory, thoracic and mediastinal disorders: Nasal congestion.
Skin and subcutaneous tissue disorders: Rash, pruritus.
Vascular disorders: Hypotension with or without syncope (including postural hypotension).

This drug may cause drowsiness, if affected, do not drive or operate machinery.

Monitor blood pressure.

Symptoms: Deep sedation leading to coma; fits, and hypotension. Management: Symptomatic and supportive treatment. Perform gastric lavage; may administer activated charcoal or a dose of ipecacuanha in case of recent ingestion. Initiate cardiac monitoring immediately and for at least 24 hours. Monitor and assist ventilation, if needed. Maintain circulatory support and control hypotension. Closely monitor temperature; carry out rewarming in case of hypothermia to avoid possible convulsions. Diazepam may be given if convulsion occurs.

Enhanced hypotensive effects with antihypertensives, diuretics, antidepressants, anxiolytics, hypnotics and moxisylyte.
Potentially Fatal: Enhanced hypotensive effect with MAOIs.

Increased rate and extent of absorption with alcohol.

Description:
Mechanism of Action: Indoramin is an α-adrenoceptor blocking agent which decreases peripheral resistance and blood pressure and relaxes the hyperplastic muscle in the prostate by selectively and competitively inhibiting postsynaptic α₁-adrenoceptors. Its actions are similar to those of prazosin. Additionally, it has also been reported to possess membrane-stabilising properties and competitive antagonism activity at histamine H₁ and 5-hydroxytryptamine receptors.
Pharmacokinetics:
Absorption: Readily and rapidly absorbed from the gastrointestinal tract. Time to peak plasma concentration: 1-2 hours.
Distribution: Plasma protein binding: >90%.
Metabolism: Extensively metabolised and undergoes first-pass metabolism.
Excretion: Via faeces (46%); urine (35%). Elimination half-life: 5 hours.

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 33625, Indoramin. https://pubchem.ncbi.nlm.nih.gov/compound/Indoramin. Accessed Oct. 25, 2023.

Store below 25°C.

Other Antihypertensives

C02CA02 - indoramin ; Belongs to the class of alpha-adrenoreceptor antagonists, peripherally-acting antiadrenergic agents. Used in the treatment of hypertension.

Anon. Indoramin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 31/07/2023.

Buckingham R (ed). Indoramin Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/07/2023.

Doralese Tiltab Tablets 20 mg (Chemidex Pharma Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 31/07/2023.

Indoramin 20 mg Film-coated Tablets (Generics [UK] Ltd t/a Mylan). MHRA. https://products.mhra.gov.uk. Accessed 31/07/2023.

Joint Formulary Committee. Indoramin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/07/2023.